Do you have palmpoplantar pustulosis?

The CSL study – A clinical trial to assess a new drug for palmpoplantar pustulosis

Palmoplantar pustulosis (PPP) is a skin condition that causes blister-like sores to show up on the palms of your hands and the soles of your feet. It can also cause cracked skin or reddened, scaly patches.

CSL324 is a new biological drug, a protein called an antibody. Antibodies are usually produced by special immune cells to fight infections (bacteria, viruses or other intruders into the body). The antibody CSL324 works by blocking the activity of a growth factor called “granulocyte-colony stimulating factor” which is responsible for stimulating the bone marrow to produce white blood cells and stem cells and release them into the bloodstream. Researchers believe this antibody may be able to help decrease inflammation in many inflammatory diseases such as PPP where white blood cells have been mobilised.

CSL324 is an experimental treatment. This means that it has not been approved for treating PPP by the Therapeutic Goods Administration in Australia.

Anticipated date that enrolment will close: TBA

Who can take part

Inclusion Criteria

  • Confirmed clinical diagnosis of PPP

Exclusion Criteria

  • History of myeloproliferative disease
  • Malignancy within 5 years except non-melanoma skin cancer, carcinoma in situ, or prostate cancer not requiring treatment
  • History of uncontrolled medical condition or active infection
  • Concurrent psoriasis

What is involved for you

  • 4 week screening period, a 24-week dose ranging, 24 week extension period and an 8 week follow up period
  • blood/urine samples
  • chest x-ray
  • weight
  • blood pressure
check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4

For more information

Quote reference number
2019.100
Annette Phemister
03 9342 4531